These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
718 related articles for article (PubMed ID: 18154821)
1. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821 [TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155 [TBL] [Abstract][Full Text] [Related]
3. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568 [TBL] [Abstract][Full Text] [Related]
6. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387 [TBL] [Abstract][Full Text] [Related]
8. Soluble mesothelin-related protein--a blood test for mesothelioma. Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I Lung Cancer; 2005 Jul; 49 Suppl 1():S109-11. PubMed ID: 15950789 [TBL] [Abstract][Full Text] [Related]
9. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779 [TBL] [Abstract][Full Text] [Related]
10. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166 [TBL] [Abstract][Full Text] [Related]
12. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Park EK; Sandrini A; Yates DH; Creaney J; Robinson BW; Thomas PS; Johnson AR Am J Respir Crit Care Med; 2008 Oct; 178(8):832-7. PubMed ID: 18583574 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Cristaudo A; Foddis R; Vivaldi A; Guglielmi G; Dipalma N; Filiberti R; Neri M; Ceppi M; Paganuzzi M; Ivaldi GP; Mencoboni M; Canessa PA; Ambrosino N; Chella A; Mutti L; Puntoni R Clin Cancer Res; 2007 Sep; 13(17):5076-81. PubMed ID: 17785560 [TBL] [Abstract][Full Text] [Related]
14. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure. Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653 [TBL] [Abstract][Full Text] [Related]
16. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology. Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183 [TBL] [Abstract][Full Text] [Related]
17. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930 [TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Landi D; Gemignani F; Landi S Occup Environ Med; 2010 Apr; 67(4):233-6. PubMed ID: 19858537 [TBL] [Abstract][Full Text] [Related]
19. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138 [TBL] [Abstract][Full Text] [Related]
20. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer. Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]